Recombinant nucleic acid construct, recombinant vaccinia virus, vaccine composition and application thereof

By designing recombinant nucleic acid constructs and screening systems with specific sequences, the problems of uneven immunization effects and cumbersome construction processes of multivalent adenovirus vaccines were solved. Safe and efficient combined prevention of human adenovirus types 3, 7 and 55 was achieved, and a multivalent adenovirus vaccine vector platform suitable for large-scale preparation was constructed.

CN121896286AActive Publication Date: 2026-04-21CHANGCHUN UNIV OF CHINESE MEDICINE
3 Cites 0 Cited by

Patent Information

Application Number
CN202610377464.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-26
Publication Date
2026-04-21
Estimated Expiration
2046-03-26

AI Technical Summary

Technical Problem

Existing multivalent adenovirus vaccines have uneven immunization effects and are complicated to construct, making it difficult to achieve safe and efficient combined prevention of human adenovirus types 3, 7 and 55.

Method used

A recombinant nucleic acid construct was designed, comprising a homologous recombination arm and an expression cassette unit. The expression cassette contains the HEXON protein-coding genes of human adenovirus type 55, 3, and 7 in a specific order. The recombinant virus was rapidly and visually screened and purified using the Cre/Loxp system and the EGFP and BrdU dual-label screening system. The antigen expression cassette was integrated into the TJ2R non-essential region of the genome of the vaccinia virus Tian Tan strain as a vector.

Benefits of technology

This approach achieves balanced, efficient, and synergistic immune protection against three prevalent adenovirus types, avoids antigen competition, improves the genetic stability of recombinant viruses and vaccine construction efficiency, and provides a safe and scalable multivalent adenovirus vaccine vector platform.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a recombinant nucleic acid construct, a recombinant vaccinia virus, a vaccine composition and application thereof, and relates to the recombinant nucleic acid construct for preventing human adenovirus infection, the recombinant vaccinia virus prepared from the recombinant nucleic acid construct, the vaccine composition containing the virus, and preparation and application of the recombinant nucleic acid construct and the recombinant vaccinia virus. The technical problems that an existing multivalent vaccine is not uniform in immune effect and tedious in construction process are solved. The invention discloses a recombinant nucleic acid construct which comprises a vaccinia virus homologous recombination arm and an expression cassette unit located between the vaccinia virus homologous recombination arm. The expression cassette unit comprises human type-55, type-3 and type-7 adenovirus HEXON protein coding genes, the type-55 gene is reverse, and the type-3 and type-7 genes are forward. The recombinant vaccinia virus constructed by the method can realize stable co-expression of multivalent antigens, and is used for preparing multivalent vaccines for preventing infection of human type 3, type 7 and type 55 adenoviruses. The method is suitable for the fields of vaccine research and development, infectious disease prevention and control, viral vector technology platforms, recombinant protein or multivalent antigen expression technology and the like.
Need to check novelty before this filing date? Find Prior Art